European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme.

@article{Bent2003EuropeanOF,
  title={European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme.},
  author={Martin van den Bent and W Grisold and Didier Frappaz and Roger Stupp and Julie D{\'e}sir and Thierry Lesimple and Christian Dittrich and Maja J. A. de Jonge and Alba A Brandes and Marc Paul Frenay and Antoine F Carpentier and Philippe Chollet and J{\'u}lio C{\'e}sar da Silva de Oliveira and Beno{\^i}t Baron and Denis Lacombe and Michael Sch{\"u}\ssler and Pierre Fumoleau},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2003},
  volume={14 12},
  pages={1732-4}
}
BACKGROUND Glufosfamide is a new alkylating agent in which the active metabolite of isophosphoramide mustard is covalently linked to beta-D-glucose to target the glucose transporter system and increase intracellular uptake in tumor cells. We investigated this drug in a multicenter prospective phase II trial in recurrent glioblastoma multiforme (GBM). PATIENTS AND METHODS Eligible patients had recurrent GBM following surgery, radiotherapy and no more than one prior line of chemotherapy… CONTINUE READING